Related Experiment Video
Updated: Oct 1, 2025
08:01
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
Published on: November 17, 2017
7.5K
Peptides as Therapeutic Agents for Atherosclerosis
C Roger White1, Mayakonda Palgunachari1, Paul Wolkowicz1
1Department of Medicine, UAB Medical Centre, Birmingham, AL, USA.
Methods in Molecular Biology (Clifton, N.J.)
|March 3, 2022
Summary
Apolipoprotein A-I mimicking peptides were developed to combat atherosclerosis. These de novo-designed peptides show promise as therapeutic agents for lipid disorders.
Area of Science:
- Biochemistry
- Cardiovascular Research
- Drug Discovery
Background:
- The amphipathic helix theory guided the design of novel peptides.
- Apolipoprotein A-I (ApoA-I) is the primary protein in high-density lipoproteins (HDL).
- ApoA-I mimicking peptides were created without homology to native exchangeable apolipoproteins.
Purpose of the Study:
- To explore the therapeutic potential of de novo-designed peptides.
- To investigate the antiatherogenic properties of ApoA-I mimicking peptides.
- To advance the development of these peptides for treating atherosclerosis and lipid disorders.
Main Methods:
- Design of an 18-amino acid residue peptide and its analogs.
- Evaluation of sequence homology to exchangeable apolipoproteins.
- Assessment of mimicking properties based on apolipoprotein A-I.
Main Results:
- Peptides were successfully designed to mimic ApoA-I properties.
- These peptides exhibit antiatherogenic potential.
- Research efforts are ongoing to develop them as therapeutic agents.
Conclusions:
- De novo-designed peptides offer a promising therapeutic strategy.
- ApoA-I mimicking peptides are being developed for atherosclerosis treatment.
- These peptides represent a significant advancement in managing lipid-mediated disorders.
Related Concept Videos
01:26Atherosclerosis III: Management
56
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.0K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.0K
01:27Coronary Artery Disease V: Interprofessional Care
52
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
52
01:30Atherosclerosis I: Introduction
144
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
144
01:23Atherosclerosis IV: Nursing Management
93
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
93
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
673
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
673